CryoPort (NASDAQ:CYRX) CFO Sells $2,756,577.29 in Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 169,427 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the sale, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 23rd, Robert Stefanovich sold 1,094 shares of CryoPort stock. The stock was sold at an average price of $8.18, for a total value of $8,948.92.
• On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The stock was sold at an average price of $8.00, for a total value of $21,944.00.
• On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The stock was sold at an average price of $7.76, for a total value of $300,312.00.

CryoPort Trading Down 1.4%

CYRX stock traded down $0.22 during midday trading on Monday, hitting $15.48. 573,254 shares of the company’s stock were exchanged, compared to its average volume of 912,079. The business has a 50-day simple moving average of $11.89 and a two-hundred day simple moving average of $10.17. The stock has a market capitalization of $780.19 million, a PE ratio of 11.47 and a beta of 1.90. CryoPort, Inc. has a 1-year low of $6.16 and a 1-year high of $16.73.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. As a group, research analysts expect that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Basepoint Wealth LLC acquired a new position in CryoPort during the 4th quarter worth $34,000. Tower Research Capital LLC TRC grew its stake in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after purchasing an additional 4,375 shares in the last quarter. AlphaQuest LLC acquired a new position in CryoPort during the 3rd quarter worth $79,000. Creative Planning acquired a new position in CryoPort during the 2nd quarter worth $96,000. Finally, Quadrature Capital Ltd acquired a new position in CryoPort during the 4th quarter worth $97,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on CYRX. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Guggenheim boosted their price objective on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Needham & Company LLC boosted their price objective on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Craig Hallum boosted their price objective on CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, June 3rd. Finally, KeyCorp boosted their price objective on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and a consensus price target of $15.11.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.